SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (456)12/16/1999 3:20:00 PM
From: Biomaven  Respond to of 52153
 
PB,

Very interesting - hadn't noticed CEGE at a premium. Maybe a mini shareholder revolt because of ABGX price appreciation? Hope that the deal gets sweetened?

Peter



To: Pseudo Biologist who wrote (456)12/16/1999 3:38:00 PM
From: Mike McFarland  Read Replies (1) | Respond to of 52153
 
I'm not sure folks own Gizzmo for
the CEGE programs--GZMO has been
treading water since October, and I
think that was about the time that
Genzyme announced the acquisition,
on the other hand I'd hate to see
that cash go away.

You were mainly interested in SAGE,
am I right? I guess before I print
out that letter I'd better ask if
they can give me a copy of the
Nature Biotech paper as well.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News